C12Y 207/12
Dual-specificity kinases
Official title: Dual-specificity kinases (2.7.12)
C12Y207/12 (Dual-specificity kinases) appears on 23 US grants and 45 published applications in this corpus.
Search patents in C12Y- Granted patents
- 23
- Published applications
- 45
- Assignees
- 33
- Inventors
- 113
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 2 | 2 |
| 2014 | 0 | 4 |
| 2015 | 2 | 0 |
| 2016 | 1 | 7 |
| 2017 | 2 | 3 |
| 2018 | 2 | 6 |
| 2019 | 3 | 3 |
| 2020 | 3 | 1 |
| 2021 | 1 | 3 |
| 2022 | 0 | 1 |
| 2023 | 1 | 2 |
| 2024 | 1 | 4 |
| 2025 | 1 | 2 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Tumor antigen peptide26 May 2026US 12,637,500 B2Niigata University
- Activating mitotic checkpoint control mechanisms28 Oct 2025US 12,454,559 B2The Regents of the University of Michigan
- Peptides and uses thereof for treating cancer12 Mar 2024US 11,926,677 B2Symthera Canada Ltd.
- MEK1 mutation conferring resistance to RAF and MEK inhibitors17 Oct 2023US 11,789,022 B2Dana-Farber Cancer Institute, Inc.
- Compositions and methods for regulating activity of inhibitor of DNA binding-2 (ID2) protein and for treating ID protein-related diseases29 Jun 2021US 11,045,525 B2The Trustees of Columbia University in the City of New York
- Compositions and methods to modulate tumor microenvironment associated long noncoding rnas23 Apr 2026US 2026/0109988 A1HAYA Therapeutics SA
- Polynucleotide for treatment of neurodegenerative disease, vector, cell, pharmaceutical composition, and screening method11 Sep 2025US 2025/0281642 A1Riken
- Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use6 Mar 2025US 2025/0073333 A1Board of Regents, The University of Texas System
- Novel peptides and uses thereof for treating cancer12 Sep 2024US 2024/0301002 A1Symthera Canada Ltd.
- Compositions and methods for treating osteoarthritis using a cd14 inhibitor18 Jul 2024US 2024/0239913 A1
Most cited
By later US patents
- Antisense inhibition of MAP kinase kinase 6 expression71US 6,033,910 AIsis Pharmaceuticals, Inc. · 2000
- MEK ligands and polynucleotides encoding MEK ligands5US 8,575,304 B2Intrexon Corporation · 2013
- Mitogen activated protein kinase (MAPK) kinase3US 6,465,618 B1Asahi Kasei Kabushikiki Kaisha · 2002
- Compositions and method for manipulating PIM-1 activity in circulatory system cells1US 8,617,534 B2San Diego State University (SDSU) Foundation · 2013
- Methods and compositions for reducing blood glucose1US 9,186,393 B2Children's Medical Center Corporation · 2015